Literature DB >> 8439983

Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.

L T Vlasveld1, E van de Wiel-van Kemenade, A J de Boer, J J Sein, M P Gallee, R T Krediet, C J Mellief, E M Rankin, A Hekman, C G Figdor.   

Abstract

A patient with renal cell cancer developed acute renal failure due to biopsy-proven acute tubulo-interstitial nephritis (AIN) in the 6th week of continuous infusion of 9 x 10(6) IU m-2 day-1 recombinant interleukin-2 (rIL-2). We investigated whether the AIN was the result of a cellular cytotoxic reaction induced by the rIL-2 treatment. The cytolytic activity of cryopreserved peripheral blood lymphocytes (PBL), isolated before and at the end of the rIL-2 treatment (at the time of AIN), was studied after 5 days of culture with or without rIL-2 or anti-CD28 and immobilized anti-CD3 antibodies. The PBL isolated before and at the end of the rIL-2 treatment showed cytolytic activity towards a number of allogeneic targets. However, only the PBL isolated at the end of the rIL-2 treatment showed, when stimulated with rIL-2 in vitro, significant cytolytic activity against an autologous renal cell line cultured from the AIN biopsy specimen and against an allogeneic renal cell cancer cell line. These PBL displayed no enhanced killing capacity towards autologous PBL and the melanoma cell line M14. These observations suggest that the AIN may be the result of a cytotoxic lymphocyte-mediated reaction induced by the rIL-2 treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439983     DOI: 10.1007/bf01741094

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  T-cell receptor-negative natural killer cells display antigen-specific cytotoxicity for microvascular endothelial cells.

Authors:  J R Bender; R Pardi; E Engleman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 2.  Characteristics and uses of IL-2 in immunotherapy.

Authors:  R L Bolhuis; G Stoter; A M Eggermont
Journal:  Biotherapy       Date:  1989

3.  Pathogenesis and therapy of interstitial nephritis.

Authors:  E G Neilson
Journal:  Kidney Int       Date:  1989-05       Impact factor: 10.612

4.  Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides.

Authors:  S D Averbuch; H A Austin; S A Sherwin; T Antonovych; P A Bunn; D L Longo
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

5.  Immune-complex glomerulonephritis secondary to nonspecific immunotherapy.

Authors:  A N Krutchik; A U Buzdar; M Akhtar; G R Blumenschein
Journal:  Cancer       Date:  1980-02       Impact factor: 6.860

6.  Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

Authors:  J Wang; A Walle; B Gordon; A Novogrodsky; M Suthanthiran; A L Rubin; H Morrison; R T Silver; K H Stenzel
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

7.  Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.

Authors:  A S Koo; C L Tso; T Shimabukuro; C Peyret; J B deKernion; A Belldegrun
Journal:  J Immunother (1991)       Date:  1991-10

8.  Membranes nephropathy associated with renal cell carcinoma. Evidence against a role of renal tubular or tumor antibodies in pathogenesis.

Authors:  H O Kerpen; J G Bhat; H D Feiner; D S Baldwin
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

9.  In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Authors:  J A Hank; P C Kohler; G Weil-Hillman; N Rosenthal; K H Moore; B Storer; D Minkoff; J Bradshaw; R Bechhofer; P M Sondel
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

10.  A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

Authors:  L T Vlasveld; E M Rankin; A Hekman; S Rodenhuis; J H Beijnen; A M Hilton; A C Dubbelman; F A Vyth-Dreese; C J Melief
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.